Product Manager Scott Myers to Present at 2nd Global Summit on Artificial Intelligence
Oncotelic Therapeutics (OTCQB:OTLC) announced that Product Manager Scott Myers will present at the 2nd Global Summit on Artificial Intelligence. The digital summit focuses on 'Pioneering the New Era: Advancing Global Development through Artificial Intelligence.' Myers will discuss the PubMed Corpus Builder, part of the Orion AI Suite developed by Sapu Bioscience
The PubMed Corpus Builder uses AI and LLMs to create comprehensive document corpora from the PubMed Central Database. It generates multiple search queries, downloads documents, and refines selection using vector search. The tool can identify documents with specific types of graphs and interpret them using multimodal technology. This system significantly accelerates the research process, allowing scientists to efficiently filter through hundreds of documents in minutes.
Oncotelic Therapeutics (OTCQB:OTLC) ha annunciato che il Product Manager Scott Myers parteciperà al 2° Summit Globale sull'Intelligenza Artificiale. Il summit digitale si concentra su 'Pionieri della Nuova Era: Avanzare nello Sviluppo Globale attraverso l'Intelligenza Artificiale'. Myers discuterà del PubMed Corpus Builder, parte della Orion AI Suite sviluppata da Sapu Bioscience.
Il PubMed Corpus Builder utilizza l'IA e i LLM per creare corpora di documenti completi dalla PubMed Central Database. Genera molteplici query di ricerca, scarica documenti e affina la selezione utilizzando la ricerca vettoriale. Lo strumento può identificare documenti con specifici tipi di grafici e interpretarli utilizzando tecnologia multimodale. Questo sistema accelera significativamente il processo di ricerca, consentendo agli scienziati di filtrare efficientemente centinaia di documenti in pochi minuti.
Oncotelic Therapeutics (OTCQB:OTLC) anunció que el Gerente de Producto Scott Myers presentará en la 2ª Cumbre Global sobre Inteligencia Artificial. La cumbre digital se centra en 'Pioneros de la Nueva Era: Avanzando en el Desarrollo Global a través de la Inteligencia Artificial.' Myers hablará sobre el Constructor de Corpus PubMed, parte de la Suite de IA Orion desarrollada por Sapu Bioscience.
El Constructor de Corpus PubMed utiliza IA y LLMs para crear corpora de documentos completos a partir de la Base de Datos Central de PubMed. Genera múltiples consultas de búsqueda, descarga documentos y refina la selección utilizando búsqueda vectorial. La herramienta puede identificar documentos con tipos específicos de gráficos e interpretarlos utilizando tecnología multimodal. Este sistema acelera significativamente el proceso de investigación, permitiendo a los científicos filtrar eficientemente cientos de documentos en minutos.
온코텔릭 치료제(OTCQB:OTLC)는 제품 관리자 스콧 마이어스가 제2회 글로벌 인공지능 서밋에서 발표할 것이라고 밝혔습니다. 디지털 서밋은 '새로운 시대의 개척자: 인공지능을 통한 글로벌 개발의 진전'에 중점을 두고 있습니다. 마이어스는 사푸 바이오사이언스가 개발한 오리온 AI 스위트의 일부인 퍼브메드 코퍼스 빌더에 대해 논의할 것입니다.
퍼브메드 코퍼스 빌더는 인공지능(AI) 및 대형 언어 모델(LLM)을 사용하여 PubMed 중앙 데이터베이스에서 포괄적인 문서 코퍼스를 생성합니다. 이 도구는 여러 검색 쿼리를 생성하고, 문서를 다운로드하며, 벡터 검색을 이용해 선택을 세밀하게 조정합니다. 이 시스템은 특정 유형의 그래프가 포함된 문서를 식별하고 멀티모달 기술을 사용하여 해석할 수 있습니다. 이러한 시스템은 연구 과정을 크게 가속화하여 과학자들이 몇 분 안에 수백 개의 문서를 효율적으로 필터링할 수 있게 합니다.
Oncotelic Therapeutics (OTCQB:OTLC) a annoncé que le Responsable Produit Scott Myers fera une présentation lors du 2ème Sommet Mondial sur l'Intelligence Artificielle. Le sommet numérique met l'accent sur 'Pionniers de la Nouvelle Ère : Avancement du Développement Mondial grâce à l'Intelligence Artificielle.' Myers discutera du Constructeur de Corpus PubMed, qui fait partie de la Suite IA Orion développée par Sapu Bioscience.
Le Constructeur de Corpus PubMed utilise IA et LLMs pour créer des corpus de documents complets à partir de la base de données centrale PubMed. Il génère plusieurs requêtes de recherche, télécharge des documents et affine la sélection à l'aide de la recherche vectorielle. Cet outil peut identifier des documents contenant des types spécifiques de graphiques et les interpréter à l'aide de la technologie multimodale. Ce système accélère considérablement le processus de recherche, permettant aux scientifiques de filtrer efficacement des centaines de documents en quelques minutes.
Oncotelic Therapeutics (OTCQB:OTLC) gab bekannt, dass der Produktmanager Scott Myers beim 2. Globalen Gipfel zur Künstlichen Intelligenz präsentieren wird. Der digitale Gipfel konzentriert sich auf 'Pioniere der neuen Ära: Förderung der globalen Entwicklung durch Künstliche Intelligenz.' Myers wird den PubMed Corpus Builder vorstellen, der Teil der Orion AI Suite ist, die von Sapu Bioscience entwickelt wurde.
Der PubMed Corpus Builder nutzt K.I. und LLMs, um umfassende Dokumentenkorpora aus der PubMed Central-Datenbank zu erstellen. Er generiert mehrere Suchanfragen, lädt Dokumente herunter und verfeinert die Auswahl mithilfe der Vektorsuche. Das Tool kann Dokumente mit spezifischen Diagrammtypen identifizieren und diese mithilfe von multimodaler Technologie interpretieren. Dieses System beschleunigt den Forschungsprozess erheblich, sodass Wissenschaftler in wenigen Minuten effizient Hunderte von Dokumenten filtern können.
- None.
- None.
AGOURA HILLS, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or “Our”), announced today that Product Manager Scott Myers, working through GMP Biotechnology Limited, our
“I am honored to be presenting. The PubMed Corpus Builder is just one of the tools we have developed that our scientists use regularly. We are proud to be pioneering cutting-edge technology throughout our company,” said Scott Myers, Product Manager.
Title: Using AI to Autonomously Find and Retrieve Large Amounts of Specific Medical Papers for Use in Cancer Research and Development
Abstract: The PubMed Corpus Builder, part of the Orion AI Suite developed by Scott Myers and others at Sapu Bioscience LLC, is designed to create a comprehensive document corpus from the PubMed Central Database based on one broad user given query and specified parameters. It utilizes LLMs to generate multiple search queries aimed at retrieving a wide range of unique documents. After downloading, vector search refines the document selection, allowing for advanced filtering, such as identifying documents with specific types of graphs, which standard search engines cannot achieve. The documents can then queried using multimodal technology, enabling the LLM to view and interpret graphs and charts as images, thus adding another level of detail to answers. Additionally, the system can conveniently email both the PubMed URLs and actual PDF files to users. The PubMed Corpus Builder dramatically speeds up the research process, allowing scientists to efficiently find and filter through hundreds of documents in minutes.
More information about the summit can be found: https://artificial-intelligence.hspioa.org/
About Oncotelic
Oncotelic (f/k/a Mateon Therapeutics, Inc.), was formed in the State of New York in 1988 as OXiGENE, Inc., was reincorporated in the State of Delaware in 1992, and changed its name to Mateon Therapeutics, Inc. in 2016, and Oncotelic Therapeutics, Inc. in November 2020. Oncotelic is seeking to leverage its deep expertise in oncology drug development to improve treatment outcomes and survival of cancer patients with a special emphasis on rare pediatric cancers. Oncotelic has rare pediatric designation for Diffuse Intrinsic Pontine Glioma (“DIPG” through OT-101) through its
Oncotelic's Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this communication regarding strategy, future operations, future financial position, prospects, plans and objectives of management are forward-looking statements. Words such as "may", "expect", "anticipate" "hope", "vision", "optimism", "design", "exciting", "promising", "will", "conviction", "estimate," "intend," "believe", "quest for a cure of cancer", "innovation-driven", "paradigm-shift", "high scientific merit", "impact potential" and similar expressions are intended to identify forward-looking statements. Forward looking statements contained in this press release include, but are not limited to, statements about future plans related to the operations of the JV, taking the JV into an initial public offering or the success thereof, the progress, timing of clinical development, scope and success of future clinical trials, the reporting of clinical data for the Company’s product candidates and the potential use of the Company's product candidates to treat various cancer indications as well as obtaining required regulatory approval to conduct clinical trials and upon granting of approval by the regulatory agencies, the successful marketing of the products; building and the success of our nanoparticle platform and the related success of launching the platform, the success of any contemplated transactions similar to the one under this press release. Each of these forward-looking statements involves risks and uncertainties, and actual results may differ materially from these forward-looking statements or may not occur at all. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during preclinical or clinical studies, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, failure of collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes, taking the Company or its affiliates through initial public offerings. These risks are not exhaustive, the company faces known and unknown risks, including the risk factors described in the Company's 2023 Annual Report on Form 10-K filed with the SEC on April 12, 2024 and in the company's other periodic filings. Forward-looking statements are based on expectations and assumptions as of the date of this press release. Except as required by law, the company does not assume any obligation to update forward-looking statements contained herein to reflect any change in expectations, whether because of new information, future events, or otherwise.
Contact Information:
For Oncotelic Therapeutics, Inc.:
Investor Relations
ir@oncotelic.com
FAQ
What is Oncotelic Therapeutics presenting at the 2nd Global Summit on Artificial Intelligence?
How does the PubMed Corpus Builder developed by OTLC work?
What are the benefits of OTLC's PubMed Corpus Builder for medical research?
When and where is Oncotelic Therapeutics (OTLC) presenting their AI tool?
